Evidence map›Paper›PMID 37515045›Full record

ArticleVaccines2023

Breakthrough SARS-CoV-2 Omicron Variant in Individuals Primed with Heterologous Vaccines Enhances Inhibition Performance of Neutralizing Antibody to BA.2 Parental Lineage.

Jidapa Szekely, Piyawut Swangphon, Natthaphon Nanakorn, Panuttha Chaimuti, Teerapat Nualnoi, Paweena Wongwitwichot, Namchoke Somapa, Denpong Somapa, Theerakamol Pengsakul

Abstract read
In one paragraph

Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jidapa SzekelyFaculty of Medical Technology, Prince of Songkla University, Hat Yai 90110, Thailand.ORCID 0000-0002-5019-1226
Piyawut SwangphonFaculty of Medical Technology, Prince of Songkla University, Hat Yai 90110, Thailand.
Natthaphon NanakornFaculty of Medical Technology, Prince of Songkla University, Hat Yai 90110, Thailand.
Panuttha ChaimutiImmunology and Virology Unit, Department of Medical Technology and Clinical Pathology, Hat Yai Hospital, Hat Yai 90110, Thailand.
Teerapat NualnoiDepartment of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai 90110, Thailand.ORCID 0000-0003-3294-1975
Paweena WongwitwichotDepartment of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai 90110, Thailand.ORCID 0000-0002-5112-0913
Namchoke SomapaMaster Labs Incorporation Co., Ltd., Bangkok 10510, Thailand.
Denpong SomapaMaster Labs Incorporation Co., Ltd., Bangkok 10510, Thailand.
Theerakamol PengsakulFaculty of Environmental Management, Prince of Songkla University, Hat Yai 90110, Thailand.ORCID 0000-0002-7313-4937

Funding

National Research Council of Thailand MET6601053SPrince of Songkla University PSUIT-CoRe 013/64
6 · The paper itself

Abstract

This study aims to analyze the neutralization ability against Omicron parental variants in five clusters of individuals with different Coronavirus disease (COVID-19) immunity backgrounds, including individuals receiving a homologous or heterologous vaccine without prior infection, recovered patients with homologous or heterologous vaccination, and recovery patients without vaccination. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) surrogate virus neutralization assay was performed on serum samples. Spearman correlation analysis showed that the percent inhibition against Omicron B.1.1.529 and BA.2 was significantly related to the period of serum collection (

Indexed as

COVID-19heterologous vaccinehomologous vaccineneutralizing antibodiesOmicron variants

Identifiers

PMID37515045
PMCPMC10383937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.